Debiopharm Group™ Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting
LAUSANNE, Switzerland, May 28, 2014 /PRNewswire/ --
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that new data on the investigational compounds Debio 1143 (SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90 inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago.
Debio 1143 is an orally available small molecule inhibitor of apoptosis proteins (IAPs) that mimics the activity of the natural second mitochondrial-derived activator of caspases (SMAC). By targeting IAPs, Debio 1143 can induce cancer cell death and potentiate the efficacy of chemo- and/or radiotherapy. Debio 1143 has been assessed in two phase I clinical studies and two phase I/II trials are ongoing in Europe.
Debio 1347/CH5183284 is a selective oral fibroblast growth factor receptor (FGFR) 1, 2, 3 inhibitor that has shown anti-cancer efficacy in several preclinical animal models in vivo. Debio 1347/CH5183284 will enable personalized treatments and will be developed with a companion diagnostic. Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying alterations of the FGFR 1, 2, or 3 genes.
Debio 0932 is a small oral molecule inhibitor of heat shock protein 90 (HSP90). Inhibition of HSP90 results in the degradation of oncoproteins that drive malignant progression and leads to cell death. Debio 0932 has shown efficacy in various mouse tumor xenografts and exhibits sustained tumor retention. Debio 0932 has been investigated in one phase I clinical study. Two phase I/II studies are ongoing in Europe in advanced non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) in combination with SOC and everolimus, respectively.
"We are very pleased to present results of our strong involvement in cancer treatment research and further establish our commitment to this challenging medical field," said Jean-Maurice Dumont, Vice-President Medical Affairs. "The ability to relieve people with cancer is an accomplishment."
List of abstracts presented at ASCO:
Abstract & Poster Compound Description of study number Debio 1143 First-in-human, pharmacokinetic (PK) and pharmacodynamics #2532 (PD) phase I study of Debio 1143 (AT406) in patients with advanced cancer. Final results. Phase I study of Debio 1143 (AT406) in combination with #7029 daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). A phase I/II randomized study of Debio 1143 combined with #TPS6097 concurrent chemo-radiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Clinical PK/PD model for Debio 1143, a novel antagonist of #2585 IAPs in cancer treatment Debio 1347 First-in-human phase I "basket" study of Debio1347 #TPS2629 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors. Debio 0932 Final results from the phase I study expansion cohort of #2550 Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors. The HALO study: A phase I-II of the oral HSP90 inhibitor #TPS2632 Debio 0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.
About Debiopharm Group™
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.
Debiopharm International SA Contact
Additional Media Contacts
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
SOURCE Debiopharm Group